{"id":10195,"date":"2026-06-20T16:47:44","date_gmt":"2026-06-20T21:47:44","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10195"},"modified":"2026-06-20T16:54:22","modified_gmt":"2026-06-20T21:54:22","slug":"nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","title":{"rendered":"Nanoscope Therapeutics participar\u00e1 en la Convenci\u00f3n Internacional BIO 2026 y en el panel de Mujeres en Biotecnolog\u00eda."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10195\" class=\"elementor elementor-10195\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><b><span data-contrast=\"none\">SAN DIEGO, CA, 22 de junio de 2026<\/span><\/b><span data-contrast=\"none\">\u00a0Nanoscope Therapeutics Inc., una empresa de biotecnolog\u00eda dedicada al desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que su cofundadora y directora ejecutiva, Sulagna Bhattacharya, participar\u00e1 en un panel de discusi\u00f3n sobre liderazgo ejecutivo organizado por Women In Bio durante la Convenci\u00f3n Internacional BIO 2026.<\/span><span data-ccp-props=\"{&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:240,&quot;335559739&quot;:160}\">\u00a0<\/span><\/p><p><span data-contrast=\"none\">Los miembros del equipo directivo de Nanoscope tambi\u00e9n asistir\u00e1n a la Convenci\u00f3n Internacional BIO y estar\u00e1n disponibles para reunirse en el Centro de Convenciones de San Diego el 22 de junio.<\/span><span data-contrast=\"none\">Dakota del Norte<\/span><span data-contrast=\"none\">-25<\/span><span data-contrast=\"none\">th<\/span><span data-contrast=\"none\">.\u00a0\u00a0<\/span><span data-ccp-props=\"{&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559738&quot;:240,&quot;335559739&quot;:160}\">\u00a0<\/span><\/p><p><b><span data-contrast=\"none\">Detalles del panel<\/span><\/b><span data-ccp-props=\"{&quot;335559738&quot;:200,&quot;335559739&quot;:120}\">\u00a0<\/span><\/p><p><b><span data-contrast=\"none\">T\u00edtulo de la sesi\u00f3n del panel:\u00a0<\/span><\/b><span data-contrast=\"none\">Construyendo organizaciones resilientes en una era de incertidumbre<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\"> <br \/><\/span><b><span data-contrast=\"none\">Fecha:\u00a0<\/span><\/b><span data-contrast=\"none\">Martes, 23 de junio de 2026<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\">\u00a0<br \/><\/span><b><span data-contrast=\"none\">Tiempo:\u00a0\u00a0<\/span><\/b><span data-contrast=\"none\">17:30 \u2013 19:30 (hora del Pac\u00edfico)<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\">\u00a0<br \/><\/span><b><span data-contrast=\"none\">Ubicaci\u00f3n:\u00a0\u00a0<\/span><\/b><span data-contrast=\"none\">GENESIS Labs, 1155 Island Avenue, San Diego, CA<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\">\u00a0<br \/><\/span><b><span data-contrast=\"none\">Audiencia:\u00a0<\/span><\/b><span data-contrast=\"none\">Liderazgo Ejecutivo \u2013 Evento P\u00fablico<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\">\u00a0<\/span><\/p><p><b><span data-contrast=\"none\">PARTICIPANTES DEL PANEL:<\/span><\/b><\/p><p><b><span data-contrast=\"none\">ORADORES:<br \/>Sulagna Bhattacharya,<\/span><\/b><span data-contrast=\"none\">\u00a0Director ejecutivo de Nanoscope Therapeutics<\/span><span data-ccp-props=\"{&quot;335559739&quot;:200}\">\u00a0<br \/><\/span><b><span data-contrast=\"none\">Tamar Grossman,<\/span><\/b><span data-contrast=\"none\">\u00a0Director ejecutivo de La Jolla Labs<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\"><br \/><strong>Erin O&#039;Donnell<\/strong>, Socio en PwC<\/span><\/p><p><strong>MODERADOR:<br \/>Katherine Andersen \u2013 <\/strong>Director de Ciencias de la Vida y Atenci\u00f3n M\u00e9dica, Banca de Innovaci\u00f3n de HSBC<strong><br \/><\/strong><\/p><p><span data-contrast=\"none\">El panel, que forma parte de la sesi\u00f3n plenaria anual de Women in Bio (WIB) durante la Convenci\u00f3n Internacional BIO 2026, reunir\u00e1 a directoras ejecutivas y l\u00edderes s\u00e9nior que han gestionado la complejidad en los \u00e1mbitos de la ciencia, el capital y la transformaci\u00f3n organizacional. Dise\u00f1ado para ejecutivos, el panel abordar\u00e1 los desaf\u00edos m\u00e1s acuciantes que enfrentan los l\u00edderes hoy en d\u00eda: tomar decisiones cruciales con informaci\u00f3n incompleta, mantener la cohesi\u00f3n y la cultura del equipo bajo presi\u00f3n y construir organizaciones capaces de resistir el cambio constante. El debate se centrar\u00e1 en liderar en entornos ambiguos, equilibrar la transparencia con la confianza, gestionar el riesgo, mantener la cultura bajo presi\u00f3n y ayudar a los equipos a adaptarse a entornos impredecibles.<\/span><span data-ccp-props=\"{&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:160}\">\u00a0<\/span><\/p><p><i><span data-contrast=\"none\">\u201cEs un honor para m\u00ed unirme a este distinguido grupo de l\u00edderes en BIO 2026\u201d.\u201d\u00a0<\/span><\/i><span data-contrast=\"none\">As\u00ed lo afirm\u00f3 Sulagna Bhattacharya, cofundadora y directora ejecutiva de Nanoscope.<\/span><i><span data-contrast=\"none\">\u00a0\u201cConstruir una organizaci\u00f3n resiliente es inseparable de nuestra misi\u00f3n de restaurar la visi\u00f3n a los pacientes que viven con degeneraci\u00f3n retiniana. Debemos liderar con claridad y prop\u00f3sito, especialmente cuando el camino a seguir es incierto.\u201d<\/span><\/i><span data-contrast=\"none\">\u00a0<\/span><span data-ccp-props=\"{&quot;335559739&quot;:80}\">\u00a0<\/span><\/p><p><span data-contrast=\"none\">Dise\u00f1ado para l\u00edderes ejecutivos, el panel ofrecer\u00e1 perspectivas pr\u00e1cticas y experiencias de primera mano para construir organizaciones capaces no solo de resistir la incertidumbre, sino tambi\u00e9n de salir de ella m\u00e1s fuertes y mejor posicionadas para cumplir sus misiones.<\/span><span data-ccp-props=\"{&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p><p><b><span data-contrast=\"none\">SOBRE NANOSCOPE THERAPEUTICS<\/span><\/b><span data-ccp-props=\"{&quot;335559738&quot;:200,&quot;335559739&quot;:80}\">\u00a0<\/span><\/p><p><span data-contrast=\"none\">Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (<\/span><a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/\/clinicaltrials.gov\/study\/NCT04945772___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo3NjVjZmIyNjAwMWM2ZjY3M2I2MzhkNzhmYzcxODZlZDo3OmIxNmI6MDc4M2IzYjZlNTZhNTU0NzE3OWM5MDFhMDE5NGE1ZWRhMDA0YTAyMjI1ODdkYWQyOTlhMmYzYjZlN2M4YmI5MzpwOlQ6Rg\"><span data-contrast=\"none\">NCT04945772<\/span><\/a><span data-contrast=\"none\">), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en SD (<\/span><a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/\/clinicaltrials.gov\/study\/NCT05417126___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo3NjVjZmIyNjAwMWM2ZjY3M2I2MzhkNzhmYzcxODZlZDo3OjdlMzA6NmZhZWRmNzBjMTY4YjRmMTc4MDU2OWZjMWM2NzYzOWY3YzQxMDlkZmZlMTEzMjk1YjlhMjU0MzNiYTZkYzI4NjpwOlQ6Rg\"><span data-contrast=\"none\">NCT05417126<\/span><\/a><span data-contrast=\"none\">) y planes para iniciar un\u00a0<\/span><a href=\"https:\/\/protect.checkpoint.com\/v2\/r01\/___https:\/\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo3NjVjZmIyNjAwMWM2ZjY3M2I2MzhkNzhmYzcxODZlZDo3OmFmYmQ6YmU5Y2JjNTYyMTBiYmM3NzIyMTg4NDNkNmNmYjU3YTE4YzhjNDExMzdhODE0ZDE2NjgyMzlkZTU3ZmMzNTQ2YzpwOlQ6Rg\"><span data-contrast=\"none\">Ensayo de registro de fase 3<\/span><\/a><span data-contrast=\"none\">\u00a0en 2026. MCO-010 ha recibido las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 ha recibido las designaciones de Sakigake y medicamento hu\u00e9rfano para distrofias retinianas hereditarias (IRD) en Jap\u00f3n y una designaci\u00f3n de medicamento hu\u00e9rfano para IRD en Arabia Saudita. Se espera que un programa de fase 2 para MCO en GA comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/span><span data-ccp-props=\"{&quot;335551550&quot;:6,&quot;335551620&quot;:6,&quot;335559739&quot;:80}\">\u00a0<\/span><\/p><p><span data-ccp-props=\"{&quot;335559739&quot;:160}\">\u00a0<\/span><\/p><p><b><span data-contrast=\"none\">CONTACTO DE PRENSA<\/span><\/b><span data-ccp-props=\"{&quot;335559739&quot;:80}\">\u00a0<br \/><\/span><b><span data-contrast=\"none\">Nanoscope Therapeutics, Inc.<\/span><\/b><span data-ccp-props=\"{&quot;335559739&quot;:60}\">\u00a0<br \/><\/span><span data-contrast=\"none\">+1 (817) 857-1186<\/span><span data-ccp-props=\"{&quot;335559739&quot;:60}\">\u00a0<br \/><\/span><a href=\"mailto:PR@nanostherapeutics.com\"><span data-contrast=\"none\">PR@nanostherapeutics.com<\/span><\/a><span data-ccp-props=\"{&quot;335559739&quot;:60}\">\u00a0<\/span><\/p><p><span data-ccp-props=\"{&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, CA,\u00a0 June 22, 2026\u00a0\u2014\u00a0Nanoscope\u00a0Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that\u00a0Co-founder and\u00a0CEO Sulagna Bhattacharya will participate in\u00a0executive leadership\u00a0panel discussion hosted by Women\u00a0In\u00a0Bio\u00a0during the 2026 BIO International Convention.\u00a0 Members of the\u00a0Nanoscope\u00a0leadership team will also\u00a0attend [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10196,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10195","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-20T21:47:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-20T21:54:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel\",\"datePublished\":\"2026-06-20T21:47:44+00:00\",\"dateModified\":\"2026-06-20T21:54:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\"},\"wordCount\":537,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"datePublished\":\"2026-06-20T21:47:44+00:00\",\"dateModified\":\"2026-06-20T21:54:22+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_BIO2026_REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/06\\\/20\\\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-06-20T21:47:44+00:00","article_modified_time":"2026-06-20T21:54:22+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel","datePublished":"2026-06-20T21:47:44+00:00","dateModified":"2026-06-20T21:54:22+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/"},"wordCount":537,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","url":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/","name":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","datePublished":"2026-06-20T21:47:44+00:00","dateModified":"2026-06-20T21:54:22+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_BIO2026_REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/06\/20\/nanoscope-therapeutics-to-participate-in-bio-international-convention-2026-and-women-in-bio-panel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in BIO International Convention 2026 and Women In Bio Panel"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10195"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10195\/revisions"}],"predecessor-version":[{"id":10200,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10195\/revisions\/10200"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10196"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}